Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Radioligand Therapy Boosts Survival in mCRPC

June 21st 2022

The prostate specific membrane antigen-targeting therapy, lutetium Lu 177 vipivotide tetraxetan, was approved by the FDA for patients with metastatic castration-resistant prostate cancer in March.

Dr. Sandhu on the Design of the MAGNITUDE trial in Prostate Cancer

June 20th 2022

Shahneen Sandhu, MD, discusses the design of the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer

June 20th 2022

Dr. Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.

Study Finds Wide Variations in Prostate Cancer Risk Within Hispanic Subgroups

June 17th 2022

Research underscores the need to subdivide Hispanics and other racial and ethnic groups to fully understand actual disparities.

Onilcamotide Fails to Reduce Risk of Progression in Prostate Cancer With Biochemical Recurrence

June 16th 2022

The peptide cancer vaccine onilcamotide failed to show superiority over placebo in terms of preventing progression in patients with prostate cancer and biochemical recurrence following curative-intent therapy, missing the primary end point of the phase 2b BRaVac trial.

Dr. Sandhu on the Safety Data Seen in the MAGNITUDE Trial in Prostate Cancer

June 14th 2022

Shahneen Sandhu, MD, discusses the safety data seen in the phase 3 MAGNITUDE trial in metastatic prostate cancer.

Early Data Make B7-H3 a Checkpoint Contender in Prostate Cancer and Beyond

June 10th 2022

B7-H3, a member of the same protein family as PD-L1, has garnered attention as one of a slew of alternative targets riding the wave of success of immune checkpoint inhibitors in cancer immunotherapy.

PSA Response Following Darolutamide Triplet Linked to OS Benefit in mHSPC

June 8th 2022

Treatment with darolutamide, androgen deprivation therapy, and docetaxel that elicited a PSA response was linked to improved overall survival in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide Lowers Risk of Metastatic Progression in Nonmetastatic CRPC

June 7th 2022

Darolutamide significantly reduced the risk of metastatic progression and improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Does Not Affect Cabazitaxel Systemic Exposure in mCRPC

June 7th 2022

Cabazitaxel can safely be combined with darolutamide in patients with metastatic castration-resistant prostate cancer.

PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPC

June 6th 2022

68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPC

June 5th 2022

The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.

177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel

June 5th 2022

177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities

Prostate Cancer Management: Future Directions in Care

May 25th 2022

Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

May 25th 2022

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Capivasertib Plus Docetaxel Continues to Demonstrate Improved Overall Survival in mCRPC

May 23rd 2022

Capivasertib plus docetaxel continued to show an improvement in overall survival compared with docetaxel alone in patients with metastatic castration-resistant prostate cancer.

Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate Cancer

May 20th 2022

Daniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.

Orteronel Plus ADT Misses OS End Point in Metastatic Hormone-Sensitive Prostate Cancer

May 20th 2022

The addition of orteronel to androgen deprivation therapy vs bicalutamide improved progression-free survival and prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer, but missed the primary end point of overall survival in the phase 2 SWOG-1216 trial.

Metastatic CRPC: Clinical Pearls and Practical Advice

May 19th 2022

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.

Addressing Bone and Visceral Metastases in Metastatic CRPC

May 18th 2022

A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.